IP Library Granted Patent US 8,222,002
Granted Patent B2
US 8,222,002 · App. 12/792,064 · Granted Jul 17, 2012

Human anti-amyloid beta peptide antibody and fragment of said antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,222,002
App. No.
12/792,064
Granted
Jul 17, 2012
Kind
B2
Abstract

A human anti-amyloid β peptide (hereinafter referred to as “Aβ”) antibody that binds to Aβ to thereby inhibit aggregation of Aβ molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, comprising a variable region of a human-derived anti-Aβ antibody, strongly reacts with Aβ to thereby inhibit its aggregation and hence may be used as a medicament for the prophylaxis and treatment of Alzheimer dementia.

Claims (17)

1. An isolated polynucleotide that encodes a human anti-amyloid β peptide 1-42 (Aβ42) antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment comprises the heavy chain CDRs 1-3 of SEQ ID NOs: 72-74, respectively, and the light chain CDRs 1-3 of SEQ ID NOs: 77-79, respectively.

2. A recombinant expression vector comprising the isolated polynucleotide according to claim 1 .

3. An isolated host cell comprising the recombinant expression vector of claim 2 .

4. A method for producing a human anti-Aβ42 antibody or antigen binding fragment thereof comprising culturing the isolated host cell of claim 3 and recovering the human anti-Aβ42 antibody or antigen-binding fragment thereof produced by the host cell.

5. A composition comprising the isolated polynucleotide according to claim 1 .

6. The isolated polynucleotide according to claim 1 , wherein the polynucleotide encodes the H chain variable region amino acid sequence of SEQ ID NO: 71 and the L chain variable region amino acid sequence of SEQ ID NO: 76.

7. The isolated polynucleotide according to claim 1 , wherein said Aβ42 is fibrillar Aβ42.

8. The isolated polynucleotide according to claim 1 , wherein said antigen-binding fragment of the antibody is Fab, Fab', F(ab') 2 , scAb, or scFv-Fc.

9. An isolated polynucleotide coding for a human anti-amyloid β peptide 1-42 (Aβ42) antibody or an antigen binding fragment of the antibody, wherein the antibody or antigen binding fragment comprises:

a) a heavy chain variable region comprising CDRs 1-3 of SEQ ID NO: 72-74, and

b) a light chain variable region fragment of a human anti-Aβ42 antibody.

10. A recombinant expression vector comprising the isolated polynucleotide according to claim 9 .

11. An isolated host cell comprising the recombinant expression vector of claim 10 .

12. A method for producing a human anti-Aβ42 antibody or antigen binding fragment thereof comprising culturing the isolated host cell of claim 11 and recovering the human anti-Aβ42 antibody or antigen binding fragment thereof produced by the host cell.

13. A composition comprising the isolated polynucleotide according to claim 9 .

14. The isolated polynucleotide according to claim 9 , wherein said Aβ42 is fibrillar Aβ42.

15. The isolated polynucleotide according to claim 9 , wherein said antigen binding fragment of the antibody is Fab, Fab', F(ab') 2 , scAb, or scFv-Fc.

Assignments (2)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Apr 15, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 050169/0778 →
CHANGE OF NAME Recorded Jan 16, 2013
From: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 029636/0944 →